



































The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
Published by the University of Cape Town (UCT) in terms 
















it	 or	 information	 derived	 from	 it	 is	 to	 be	 published	without	 full	
acknowledgement	 of	 the	 source.	 The	 thesis	 is	 to	 be	 used	 for	
private	study	or	noncommercial	research	purposes	only.	
	



























































































































































































































































































































































































































































































Variable	 Type	 Definition	 Categories	
Age	 Continuous	 Independent	 >18	
Sex	 Categorical	 Independent	 Male	
Female	





HIV	status	 Categorical	 Independent	 Negative	
Positive	
CD4	 Continuous	 Independent	 >20+	
Previous	TB	 Categorical	 Independent	 No		
Yes	
HbA1c	 Continuous	 Independent	 >2+	



































































































































































































































































































































































































































































































































































































































































































WEAVER(43)		 1974	 Cross	sectional		 Atlanta,	Usa		 TB	Hospital	 11%	(23/205)	 Yes	 -	
MARAIS(44)		 1980	 Cross	sectional	 Pelonomi,	South	
Africa	
Pelonomi	Hospital	 2.1%	(9/436)	 Yes	 -	
JAIN	ET	AL(61)		 1985	 Cross	sectional	 Jaipur,	India	 Hospital	 6.9%	(16/230)	 No	 No	
MORRIS	ET	AL(46)		 1992	 Case	Control		 San	Antonio,	Usa	 Chest	Hospital	 		 Yes	 No	





1997	 Case	Control		 Abha,	Saudi	Arabia	 Hospital		 		 No	 No	
PEREZ-GUZMAN	ET	
AL(47)	
2001	 Case	Control	 Mexico	City,	Mexico	 Chest	Hospital	 		 Yes	 Yes	
SHAIKH	ET	AL(48)	 2003	 Cross	sectional	 Riyadh,	Saudi	Arabia	 Chest	Hospital	 27%	(187/692)	 Yes	 Yes	
	WANG	ET	AL(55)	 2005	 Cross	sectional	 Taiwan	 Tertiary	Care	Referral	
Centre	
21.5%	(99/461)	 No	 Yes	
	JABBAR	ET	AL(49)	 2006	 Case	Control		 Karachi,	Pakistan	 Tertiary	Hospital		 	 Yes	 -	
TATAR	ET	AL(56)	 2009	 Case	Control	 Izmir,	Turkey	 TB	Hospital	 7.3%	(78/1063)	 -	 Yes	









2012	 Case	Control		 Lisbon,	Portugal	 Respiratory	Hospital	 		 Yes	 Yes	
ALAVI	ET	AL(57)	 2014	 Cross	sectional	 Iran	 TB	Referral	Hospital		 24%	(36/149)	 -	 Yes	
	 25	










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































	 	 	 	 0,000	 	 0,000	 	 0,000	
<25	years	
	 23	(6,8)	
	 13	(15,5)	 5	(2,5)	 	 1	(4,8)		 	 4	(12,1)		 	
25	–	35	years	 109	
(32,3)	
	 35	(41,7)	 68	(34,2)	 	 1	(4,8)		 	 5	(15,2)		 	
35	–	45	years	 121	
(35,9)	
	 19	(22,6)	 88	(44,2)	 	 3	(14,3)	 	 11	(33,3)	 	

















































































































	 OVERALL	(N=54)	 NEW	DM	(N=26)	 OLD	DM	(N=28)	
Diagnostic	
test	(%)	
FBG	 42,6	(29,2	–	56,8)	 30,8	(14,2	–	51,8)	 53,6	(33,9	–	72,5)	
2hBG	 18,5	(9,3	–	31,4)	 34,6	(17,2	–	55,7)		 3,6	(0,09	–	18,3)	








































































Normal	radiograph	 38	(11,3)	 		 3	(3,6)	 1	(4,8)	 0,508	 30	(15,1)	 0,006	 5	(15,2)	 0,039	
Any		
opacification	
273	(81,0)	 	 76	(90,5)	 21	(100)	 0,156	 150	(75,4)	 0,004	 26	(78,8)	 0,123	
Upper	lobe	opacification	 240	(71,2)	 		 73	(86,9)	 17	(81,0)	 0,348	 129	(64,8)	 0,000	 21	(63,6)	 0,004	
Lower	lung	field	opacification	 181	(53,7)	 	 51	(60,7)	 16	(76,2)	 0,187	 103	(51,8)	 0,167	 11	(33,3)	 0,008	
Any	cavitation	 161	(47,8)	 		 57	(67,9)	 11	(52,4)	 0,184	 83	(41,7)	 0,000	 10	(30,3)	 0,000	
Upper	lobe	cavitation	 143	(42,4)	 	 54	(64,3)	 11	(52,4)	 0,315	 70	(35,2)	 0,000	 8	(24,2)	 0,000	
Lower	lung	field	cavitation	 35	(10,4)	 		 6	(7,1)	 5			(23,8)	 0,041	 22	(11,1)	 0,314	 2	(6,1)	 0.598	
Miliary	pattern	 9	(2,7)	 	 3	(3,6)	 0	 0,505	 5	(2,5)	 0,439	 1	(3,0)	 0,680	
Pleural	effusion	 81	(24)	 		 16	(19,1)	 6	(28,6)	 0,249	 53	(26,6)	 0,175	 6	(18,2)	 0,914	

















































































81	(96,4)		 142	(84)	 0,004	 21	(100)	 21	(84)	 0,078	
Any	opacification	 76	(90,5)	 126	(74,5)	 0,003	 21	(100)	 19	(76)	 0,019	
Upper	lobe	
opacification	
73	(86,9)	 107	(63,3)	 <0,001	 17	(81,0)	 14	(56)	 0,072	
Lower	lung	field	
opacification	
51	(60,7)	 89	(52,7)	 0,225	 16	(76,2)	 10	(40)	 0,014	
Any	cavitation	 57	(67,9)	 71	(42)	 <0,001	 11	(52,4)	 6	(24)	 0,047	
Upper	lobe	cavitation	 54	(64,3)	 59	(34,9)	 <0,001	 11	(52,4)	 5	(20)	 0,022	
Lower	lung	field	
cavitation	




















81	(96,4)		 27	(90)	 0,176	 21	(100)	 7	(87,5)	 0,309	
Any	opacification	 76	(90,5)	 24	(80)	 0,133	 21	(100)	 7	(87,5)	 0,576	
Upper	lobe	
opacification	
73	(86,9)	 22	(73,3)	 0,087	 17	(81,0)	 7	(87,5)	 0,721	
Lower	lung	field	
opacification	
51	(60,7)	 14	(46,7)	 0,182	 16	(76,2)	 1	(12,5)	 0,011	
Any	cavitation	 57	(67,9)	 12	(40)	 0,007	 11	(52,4)	 4	(50)	 0,258	
Upper	lobe	
cavitation	
54	(64,3)	 11	(36,7)	 0,009	 11	(52,4)	 3	(37,5)	 0,134	
Lower	lung	field	
cavitation	

































TBDM	 	0,79				(0,44	-	1,43)	 0,437	 	1,71				(0,56	-	5,21)	 0,346	 	1,41				(0,58	-	3,43)	 0,450	 3,92				(1,04	-	14,73)	 0,043	 2,28				(0,95	-	5,50)	 0,065	 4,90				(0,90	-	26,5)	 0,065	
TBHIV	 	0,58				(0,34	-	0,93)	 0,025	 	0,63				(0,37	-	1,09)	 0,099	 	0,94				(0,44	-	2,02)	 0,880	 1,39					(0,53	-		3,63)	 0,499	 	1,73			(0,68	-	4,42)	 0,248	 2,67				(0,76	–	9,42)	 0,127	
TBDMHIV	 -	 	 	0,46				(0,20	–	1,03)	 0,061	 -	 	 0,63					(0,13	-	2,80)	 0,076	 -	 	 1,75				(0,59	-	5,21)	 0,319	
Previous	
TB	history	
	2,00				(1,22	-	3,25)	 0,006	 	2,18				(1,30	-	3,64)	 0,003	 	2,28					(1,11	-	4,68)	 0,025	 2,14					(1,02	-	4,46)	 0,043	 0,76					(0,31	-	1,85)	 0,547	 0,74				(0,30		-	1.83)	 0,509	
Smoker	 	0,64				(0,38	-	1,07)	 0,091	 	0,51				(0,29	-	0,88)	 0,016	 	0,90					(0,38	-	2,17)	 0,820	 -	 	 0,56					(0,19	-	1,68)	 0,302	 -	 	
Age	 	1,00				(0,98	-	1,02)	 0,747	 -	 	 	1,01					(0,99	-	1,04)	 0,512	 -	 	 1,02					(0,98	-	1,05)	 0,304	 -	 	






















































































































































































































































































































OVERALL RESEARCH OBJECTIVE  
The main aim of this study is to investigate the incremental yield and best screening algorithms for 
diabetes mellitus (DM) and tuberculosis (TB) among a) newly diagnosed TB patients and b) patients 
attending diabetic clinics, respectively.  
Specific aims:  
•  To assess the prevalence of DM among Cases  
•  To evaluate the best performing algorithms to diagnose DM in Cases  
•  To measure the prevalence of TB among diabetes patients   
BACKGROUND  
TB remains a leading cause of death globally, with an estimated 8.8 million new cases reported every 
year, threatening the goal of global TB elimination by year 2050 (1). Tackling this challenge will 
require not only improvements in diagnostic and treatment services, but identification and reduction of 
risk factors that increase susceptibility for TB. Medical conditions that impair immune function, such 
as malnutrition, alcoholism or HIV co-susceptibility for TB. Medical conditions that impair immune 
function, such as malnutrition, alcoholism or HIV co-infection, can increase the likelihood of infection 
or reactivation of latent TB. Increasing evidence suggests that DM is also a significant risk factor for 
TB. In a recent systematic review, the relative risk for TB in diabetic patients was 3.1 (2). The strength 
of this link was influenced by geographic/ethnic differences, and  
young people were at particularly high risk; in India, DM is thought to be associated with nearly 15% 
of pulmonary Cases (3). However, these studies had a number of limitations. In particular, very few 
were carried out in low-income countries, with none in Africa, raising uncertainty about the strength of 
DM-TB association and benefit of bi-directional screening for DM and TB in these settings with high 
TB/HIV prevalence and AN increasing burden of DM. Practical guidance on when to suspect, and 
how best to diagnose, diabetes in TB patients, and how to confirm or exclude it are lacking. The 
World Health Organisation recommends HbA1c as a diagnostic test for diabetes with a cut-off value 
of 6.5% (4). However, less clear is the diagnostic value of results below the WHO cut-off (there is an 
argument for population-specific cut-off values). A study conducted on a population of mixed-ancestry 
in Cape Town showed that this cut-off value was sub-optimal (erasmus). Furthermore, it is not known 
how the diagnostic performance of the cut-off is affected by acute illness, such as TB. A point of care 
HbA1c test could make diabetes screening more effective and potentially more affordable. A study 
comparing POC devices found that only Afinion and DCA Vantage met the diagnostic performance 
criteria (6). There are also insufficient data on which to base TB screening guidelines for diabetic 
patients.  
The growing epidemic of diabetes as a threat to TB control  
While 95% of patients with TB live in the low- and middle-income countries, 70% of patients with DM 
also live in these same countries. It is estimated that, worldwide in 2010, there were 285 million 
people with DM, and the number predicted to rise to 438 million by 2030, making DM one of the most 
common NCDs globally (7). The majority of this increase will occur in developing countries where TB 
remains endemic. Diabetes on this scale is likely to pose another threat for global TB control. The 
potential public health and clinical importance of this seems to have been largely ignored until 
recently. Recent joint consultations by International Union Against Tuberculosis and Lung Disease, 
the World Diabetes Foundation and the World Health Organization emphasised the urgent need for 
research in this area (10). There is also a paucity of data on whether DM is associated with a high 
prevalence of subclinical TB among patients attending diabetic clinics, as observed in HIV-1 co-
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infected persons (13). This has major importance when considering TB screening strategies, with 
potential for amplification by transmission within diabetic clinics and also potentially serious 
consequences of false-negative TB screening. Research is therefore required to develop appropriate 
and evidence-based guidelines for TB screening among persons with DM.  
Diabetes, HIV and TB in South Africa and the Western Cape  
South Africa is among the 22 high TB burden countries globally, and also has the highest urban: rural 
ratio in sub-Saharan Africa, with 62% of the population being urban dwellers (17). Urbanisation, in 
addition to rapid epidemiological and demographic transition has resulted in a rising burden of NCDs. 
The global burden of disease study demonstrated that in Southern Africa, while HIV and TB rank first 
and 4th in the top ten causes of morbidity, 50% of the causes of morbidity are non-communicable; 
diabetes is ranked 7th. A community survey conducted in 2008/9 from Cape Town townships showed 
a DM prevalence of 13.1% (95% CI: 11.0- 15.1) (26).  
Mortality rates from NCDs are also increasing; diabetes was the 6th leading causes of mortality in 
South Africa in 2010. In the Western Cape, the province within which Cape Town is located, TB and 
DM are the top 2 causes of mortality. Against this background, the prevalence of HIV, the strongest 
known risk factor for TB, remains high, with 70% of TB cases being HIV-infected in Khayelitsha  
PLAN OF INVESTIGATION  
Setting and study population 
The study will be conducted in Khayelitsha, reputed to be the fastest growing township in South 
Africa. Khayelitsha is located 30km from Cape Town with a population of over 500,000 predominantly 
black Africans, HIV antenatal prevalence of 28% and a TB case-notification rate of >1600/100,000 
(27). The largest TB clinic in Khayelitsha is Ubuntu clinic. A survey by the Department of Health 
reported 1187 newly registered TB cases were diagnosed at Ubuntu clinic in 2011.  
Study design  
DM Screen in TB patients  
We will recruit consecutive TB cases at Ubuntu clinic, prior to initiation of TB treatment. We will record 
demographic, medical and drug history, HIV status and (if positive) date of initiation of ART, regimen, 
and CD4 count, as well as clinical, microscopic and radiological characteristics of TB at diagnosis. In 
addition we will document other risk factors for diabetes, such as family history, body mass index 
(BMI), and waist circumference. Before starting TB chemotherapy blood samples will be collected to 
measure fasting blood glucose and oral glucose tolerance test, and HbA1c performed using Afinion, a 
validated HbA1c Point of care test. Patients will be considered to be diabetic if 1) the diagnosis is 
known at presentation, 2) they are taking oral hypoglycaemic therapy and/or insulin or 3) as per case 
definitions. Previous studies have suggested that it may be more reliable to screen for diabetes later 
in the course of TB treatment rather than at the start (11), because inflammation/cytokine stimulation 
associated with active TB may elevate blood glucose levels resulting in false positive diabetes 
diagnoses if tests are performed too early. We will, therefore, repeat fasting blood glucose and HbA1c 
tests after 2 months of TB treatment. Patients with a new diagnosis will be referred to the DM clinic for 
standard care. HIV testing is offered routinely to all patients with TB.  
TB screen in diabetic patients  
We will recruit consecutive diabetes patients presenting to the primary care diabetes clinic at 
Khayelitsha day hospital. A TB screen will be performed as per case definition. We will also record 
demographic, medical and drug history, previous TB and TB contact history, as well as HbA1c to 
measure glycaemic control at the time of recruitment.  
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Subclinical TB disease Smear microscopy positive for acid fast bacilli Isolation  
Outcome measures  
Primary outcome 
 
      • The best performing screening algorithm to diagnose DM in TB patients  
Secondary outcomes  
•  Accuracy of established intensified TB case-finding strategies among diabetics  
•  Prevalence of diabetes in TB patients  
•  Prevalence of TB in diabetics, including subclinical TB disease  
•  Effect of diabetes on TB clinical presentation (number and duration of pulmonary TB 
symptoms, TB  
sputum smear and microscopy results, CXR findings, non-pulmonary manifestation of disease) and/or 
treatment outcomes of TB (2 month TB sputum clearance, completion and cure rates)  
Sample size and power calculations  
Assuming a DM prevalence of 24% in TB patients (based on a TB/DM risk ratio of 2 and DM 
prevalence in the general population of 12%), in order to have 80% statistical power and a screening 
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tool sensitivity of 60%, a sample size of 1537 TB cases is required in Malawi and South Africa 
respectively. This sample size will provide sufficient power to define and investigate different potential 
DM screening algorithms in TB patients.  
For the TB prevalence in DM patients study, a sample size of 457 diabetic patients is required, 
assuming TB prevalence of 5% and at 2% precision.  
Statistical analysis plan  
The prevalence of diabetes and TB will be based on the respective gold standard diagnostic tests. We 
will calculate the sensitivity, specificity, positive and negative predictive values of the screening tools 
to diagnose  
DM in TB cases, and TB in DM patients, using OGTT and TB culture gold standards, respectively. 
Among TB cases, risk factors associated with DM will be analysed using logistic regression. The 
model will be built manually with nested models compared using the likelihood ratio test. The Akaike’s 
Information Criterion (AIC) will be used to compare non-nested models with a significantly lower AIC 
(>10%) indicating an improved model. In addition, outlying and influential observations will be 
identified and potential effect modification assessed using interaction variables.  
To develop and evaluate a DM screening algorithm in TB cases, based on symptom screening, HIV 
status, ART, age, sex, BMI, waist circumference, and DM family history. Multivariable logistic 
regression analysis will then be performed to develop diagnostic models for DM using OGTT findings 
as the gold standard. A reduced clinical model without additional investigations will first be derived. 
These tests will then be added singly to the reduced clinical model and then simultaneously to explore 
the added predictive value of a single test and of combined tests, respectively. The ability of a 
multivariable model to discriminate persons with DM from those without will be assessed using 
Receiver Operator Characteristic curve and Area Under the Curve analysis. Significance testing will 
be done using a combination of two-sided p-values (p<0.05) and 95% confidence intervals. All data 
will be analysed using STATA 12.0 (StataCorp, College Station, TX, USA)  
Ethical considerations  
This study has received ethics approval from the University of Cape Town Human Ethics committee 
(HREC Ref: 403/2011). A written consent will be obtained from all participants who will be given 
detailed explanation of the study. An information sheet will be available both in English and Xhosa.  
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Anticipated overall outputs and impacts  
This study performed at such an important time, with respect to the emerging diabetes epidemic in 
sub- Saharan Africa, will provide an invaluable set of data to document the strength of association 
between diabetes and TB and its clinical/public health impact. Data of this quality does not exist in the 
current literature on the link between TB and diabetes in sub-Sahara Africa; hence we expect this 
study to produce a series of high quality publications. Additionally, the study is designed to raise 
further research questions and provide some of the ground work needed, for example to determine 1) 
optimal screening models 2) whether diabetes influences recurrence of TB or anti-tuberculosis drug 
resistance 3) the need to develop randomised controlled trials of efficacy of interventions, such as TB 
chemoprophylaxis in people with diabetes, to improve outcomes of both diseases.  
 
Contingency plans  
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Participant Study Number: DBSN- __ _ 
Step 1 Demographic Information **(start on page 8)** 
Date Response Code 
13 Interviewer name 114 
14 Date dd mmm yyyy 115 
Baseline TB group assignment (as per log book) 
TB Case: TB diagnosed on smear/XperVculture PLUS TB treatment 
to be commenced 
15 TB case 1 116 TB Control: Symptoms resolved PLUS TB investigations negative to 
date PLUS no TB treatment commenced TB control 2 
If excluded, do not proceed 
EXPANDED: Demographic Information 
No formal schooling 1 
Started primary school but did not 2 
complete 
What is the highest level of education you have Primary school completed 3 
completed? Started high school but did not 
16 complete 4 cs 
High school completed 5 
College/University completed 6 
Post graduate degree 7 
Refused 88 
Never married 1 
Currently married 2 
Separated 3 




Government employee 1 
Non-government employee 2 
Which of the following best describes your main work Self-employed 3 
status over the past 12 months? Non-paid 4 
Student 5 
18 Homemaker 6 cs 
Retired 7 
Unemployed (able to work) 8 
Unemployed (unable to work) 9 
Unemployed (receiving grants) 10 
Refused 88 
19 How many people older than 18 years, including Number of people C9 yourself, live in your household? 
Per week C10a 
I I I I I I I I 
Taking the past year, can you tell me what the average OR per month C10b 
income of the household (induding grants) have been? I I I I I I I I 
20 (RECORD ONLY ONE, NOT ALL 3) 
OR per year C10c 




Participant Study Number: DBSN-
Step 2 Behavioural Measurements 
CORE: Tobacco Use 
Now I am going to ask you some questions about various health behaviours. This includes things like smoking, drinking alcohol, eating fruits 
and veoetables and ohvsical activitv. Let's start with tobacco. 
Question Response Code 
Do you currently smoke any tobacco products, such Yes 1 
21 as cigarettes, cigars or pipes? T1 
No 2 If No, go to q26 
Yes 1 
22 Do you currently smoke tobaoco products daily? T2 
No 2 If No, go to q26 
How old were you .Alen you first started smoking Age (years) T3 23 dai y? Don't know 77 L..l...J If Known, oo to 025 
Do you remember how long ago it was? In Years L..l...J T4a 
24 (RECORD ONLY 1, NOT ALL 3) OR in Months L..l...J T4b 
Don't know 77 
OR in Weeks T4c L..l...J 
Manufactured cigarettes L..l...J T5a 
On average, how many of the followi,g do you smoke Han~led cigarettes L..l...J T5b 
each day? 
Pipes full of tobacco T5c L..l...J 
25 (RECORD FOR EACH TYPE) 
Don't Know 77 
Cigars L..l...J T5d 
Other L..l...J T5e 
Other (please specify): T5other 
EXPANDED: Tobacco Use 
Question Response Code 
Yes 1 
26 In the past, did you ever smoke daily? T6 
No 2 If no, go to q29 
27 How old were you when you s.topped smoking daily? 
Age [years) 
T7 
Don't Know 77 L..l...J If known, ao to a29 
How long ago did you stop smoking daily? Years ago L..l...J T8a 
28 (RECORD ONLY 1, NOT ALL 3) OR Months ago L..l...J T8b 






Participant Study Number: DBSN-
CORE: Diet 
The next questions ask about the fruits and vegetables that you usually eal As you answer these questions please think of a typical week in 
the last year. 
Question Response Code 
37 
In a typical week, on how many days do you eat fruit? Number of days 0 1 0on, Know77 L...L.J If Zero days, go to q39 
38 How many servings of trua do you eat on one of those Number of servin~s D2 days? 0on, Know77 L...L.J 
39 In a typical week, on how many days do you Number of days D3 eat vegetables? 0on, Know77 L...L.J If Zero davs, qo to C/41 
40 How many servings of vegetables do you eat on one of 
Number of servings D4 
those days? Don't know 77 L...L.J 
EXPANDED: Diet 
Vegetable / fish/ olive oil 1 
Animal fats 2 
Butter or ghee 3 
Whal type of oil or fat is most often used for meal Margarine 4 D5 
41 preparation il your household? Other 5 If Other, r,o to 05other 
None in particular 6 
None used 7 
Don't know 77 
Other D5other 
On average, how ma:iy meals per week do you eat that Number 
42 were nol ptepared al home? By meal, I mean breakfast, D6 
lunch and dinner. Don't know 77 L...L.J 
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Participant Study Number: DBSN-
CORE: Physical Activity 
Next I am going to ask you about the time you spend doing different types of physical activity in a typical week. Please answer these questions 
even if you do not consider yourself to be a physically active person. 
Think first about the time you spend doing work. Think of work as the things that you have to do such as paid or unpaid work, study/training, 
household chores, harvesting food/crops, fishing or hunting for food, seeking employment. In answering the following questions 'vigorous-
intensity activities' are activities that require hard physical effort and cause large increases in breathing or heart rate, 'moderate-intensity 
activities' are activities that reouire moderate ohvsical effort and cause small increases in breathina or heart rate. 
Question Response Code 
Work 
Does your work involve vigorous-<nlensity activity that Yes 1 
43 causes large inaeases in breathing ()( heart rate like P1 canying ()( lifting heavy loads, <figging or construction 
""'* for al least 10 minutes continuously? No 2 If No, go to q46 
44 In a typical week, on how many days do you do Number of days P2 vigorous-intensity activities as part of your work? L...l.....J 
45 How much time do you spend doing vig()(OUs-<nlensity P3 activities al work on a typical day? Hours : minutes (a-b) 
hrs mins 
Does your work involve moderate-intensity activity that Yes 1 
46 causes small inaeases in breathing or heart rate such P4 as brisk walking or canying light loads for al least 10 
minutes continuously? No 2 If No, go to q49 
47 In a typical week, on how many days do you do Number of days P5 moderate-intensity activities as part of your work? 
How much time do you spend doing moderate-intensity P6 48 activities al work on a typical day? Hours : minutes (a-b) 
hrs mins 
Travel to and from places 
The next questions exclude the physical activities at work that you have already mentioned. 
Now I would like to ask you about the usual way you travel to and from places. For example to work, for shopping, to market. to place of 
worship. 
Do you walk ()( use a bicycle for al least 10 minutes Yes 1 49 P7 continuously lo get lo and from places? No 2 If No, go to q52 
In a typical week, on how many days do you walk ()( 
PB 50 bicycle f()( at least 10 minutes continuously to gel to Number of days 
and from places? 
51 How much time do you spend walking ()( bicycling for P9 travel on a typical day? Hours : minutes (a-b) 
hrs mins 
	 83	
Participant Study Number: DBSN-
CORE: Physical Activity, Continued 
Question Response Code 
Recreational activities 
The next questions exclude the work and transport activities that you have already mentioned. 
Now I would like to ask you about sports, fitness and recreational activities (leisure). 
Do you do any vigorous-intensity sports, fi1ness or Yes 1 recreational (leisure) activities that cause large 
52 increases in breathing or heart rate like running or P10 
foolbaU for at least 10 minutes continuously? 
No 2 If No, go to q55 
In a typical week, on how many days do you do 
P11 53 vigorous-intensity sports, fi!ness or reaeational Number of days 
(leisure) activities? L..l...J 
How much time do you spend doing vigorous-intensity P12 54 sports, fi!ness or recreational activities on a typical day? Hours : minutes (a-b) 
hrs mins 
Do you do any moderate-intensity sports, fi1ness or Yes 1 
recreational (leisure) activities that cause a small 
55 increase in breathing or heari rate such as brisk P13 
walking, cycling, swimming, soflba/1 for al least 10 
minutes continuously? No 2 If No, go to q58 
In a typical week, on how many days do you do 
P14 56 moderate-intensity sports, filr,ess or reaeational Number of days 
(leisure) activities? L..l...J 
How much time do you spend doing moderate-intensity P15 57 sports, fi!ness or recreational (leisure) activities on a Hours : minutes (a-b) typical day? hrs mins 
Sedentary behaviour 
The following question is about sitting or reclining at work, at home, getting to and from places, or with friends including time spent sitting at a 
desk, silting with friends, traveling in car, bus, train, reading, playing cards or watching television, but do not include time spent sleeping. 
58 How much time do you usually spend sittilg or reclining P16 
on a typical day? Hours : milutes (a-b) 
hrs mins 
A NNEX RE T b d u 0 ecompele ff by sla member 
DIABETES HISTORY 
Question Response Code 
Yes 1 
59 Any ramay histo,y of di,,bctcs? R1 
No 2 
Have you ever had diabetes during ~nancy Yes 1 60 R2 (gestational diabetes)? No 2 
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Participant Study Number: DBSN-
Step 3 Biochemical Measurements 
CORE: Blood Glucose and HbA1c 
Quest ion Response Code 
61 Blood preSSll'e I 
--- ---
J1 
During the past ~12 hours have you had anything to Yes 1 
eat eo< drink, other than water? 
62 
If yes, ccmplete STEPS 1 and 2, and re-schedule 
B1 appointment for blood tests: No 2 
Date: 
dd mmm WW 
Fasting blood glucose and HbA1c HOll'S : minutes L..l...J L.L.J 
63 B5 
Fasting glucose mmol/l I I I I L.J 
HbA1c% L..l...J L.L.J 
64 Oral glucose tolerance lest 
HOll'S : minutes L..l...J L.L.J B6 
2 hour glucose mmol/l I I I I L.J 
CORE: B!lood Lipids 
65 
Total cholesterol 
B8 mmol/l L..l...J L.L.J 
EXPANDED: Triglycerides and HDL Cholesterol 
66 
Triglycerides 
mmot/1 L..l...J L..l...J B10 
67 
HDl. Cholesterol 
mmol/1 L.J L.L.J B1 1 
Return Date Response Code 
68 
Appointment dale for diabetes and cholesterol results 
812 (1 week) dd mmm yyyy 
69 
Appointment dale for completion of step 4 













CXR	Reader		 	 	Reader	1				 	Reader	2				 	Reader	3				 	Consensus	
	




1.	Parenchymal	abnormalities	 	 	Yes	 	 	No	
	




Airspace	Opacities	present		 	Yes	 	 	No	 	 	Maybe	 	Not	visible	
	
Location	of	Airspace	Opacities	 	 	RUL	 	 	LUL	
	 	 	 	 	 	RML	
	 	 	 	 	 	RLL	 	 	LL	
	




Cavities	present	 	 	 	Yes	 	 	No	 	 	Maybe	 	Not	visible	
	
Location	of	Cavities	 	 	 	RUL	 	 	LUL	
	 	 	 	 	 	RML	








2.	Pleural	effusion	(abnormalities)	 	Yes	 	 	No	 	 	Maybe	 	Not	visible	
	 	 	 	 	 	
Location	of	pleural	effusion	 	 	 	Left	 	 	Right	 	 	Bilateral	
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3.	Lymphadenopathy	 	 	 	Yes	 	 	No	 	 	Maybe	 	Not	
visible	
	
Location	of	lymphadenopathy	 	 	 	Right	hilar	 	 	Left	hilar	 	 	Bilateral	




4.	Cardio	thoracic	ratio	increased	(>0.5)		 	Yes	 	 	No	
	
	
RMCD																					.	 							cm	 	 LMCD																																.	 	 cm	 	 MTD				 															.	 	 cm	
	
	




5.	Overall	assessment:	CXR	normal?		 	Yes	 	 	No	
	
	
TB-related	CXR	findings?	 	 	 	 	Yes	 	 	No	
	
	






PA	 	 	Acceptable	 												 	Poor	but	readable	 														 	Not	acceptable	 	 	No	readable	
	



































Institute of Infectious Diseases and Molecular Medicine 
Faculty of Health Sciences 
Observatory 7925 
South Africa 




Epidemiology of Diabetes, TB and HIV co-infection in a high HIV/TB burden 
setting 
 
INFORMED CONSENT and INFORMATION FORM 
 
My name is _______________________ 
I wish to invite you to participate in a study that is trying to assess the interaction between 
tuberculosis (TB), HIV and Diabetes. This study is being run by the Institute of Infectious Diseases 
and Molecular Medicine at the University of Cape Town. Dr Tolullah Oni is the Principal Investigator. 
 
Firstly, I wish to explain to you why this research is being done: 
 
TB is a disease that is seen very commonly in Cape Town and, indeed, in most of South Africa. It is 
caused by bacteria that people breathe in and the infection results in cough, fevers and weight loss. 
The disease is more common, and can be more severe, in patients with HIV infection. 
 
Diabetes is a disease caused by the body’s inability to control sugar levels. This disease is becoming 
increasingly more common worldwide and in South Africa due to reduced exercise and increasing 
obesity. Previous studies have shown that like HIV, diabetes increases the risk of TB.  But there are a 
few things we still do not know: 
1. We do not know how much diabetes (and risk factors such as high cholesterol) there is in this 
setting.  
2. We also do not know if the increasing levels of diabetes are contributing significantly to the 
TB epidemic, and  
3. Although we know that HIV increases the risk of TB, we do not know if having HIV and 
diabetes further increases the TB risk. In other words, we do not know if a person with HIV 
and diabetes is at higher risk of TB than a person with HIV and no diabetes. 
 
In addition, we know that low  vitamin D levels increase the risk of TB. We also know that many 
people in Cape Town have very low levels of vitamin D. Therefore we also wish to measure your 
vitamin D level and see how this affects the risk of TB and recovery from TB in TB patients. 
 
We request your participation in this study either because you are being investigated for TB, because 
you have been diagnosed with diabetes, or because you have recently undergone HIV counselling 
and testing (HCT).  
 
As part of this study, we will check your blood for HIV and check your sputum (spit) for TB.  We will 
also check you for Diabetes using the following tests: 
We will ask you to come again before eating or drinking anything and check your sugar level that 
morning and 2 hours later after giving you a sugary drink. You must not eat or drink anything else during 
these 2 hours. We will also do an HbA1c test, a blood test for diabetes and check your blood cholesterol 
level. We will pay 30 Rand travel expenses for this purpose. 
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We will also take blood to measure your vitamin D level. If we diagnose HIV, we will give you a 
referral letter to take to any HIV clinic of your choice where baseline bloods will be done and your 
eligibility for antiretroviral therapy can be assessed. If TB is found, we will also give you a letter to take 
to your nearest TB clinic as it will be important to start TB treatment as soon as possible. If diabetes is 
diagnosed, we will write a referral letter for you and advise you of your nearest diabetes club where 
you can be started on appropriate treatment and receive regular advice on diet and lifestyle. If high 
cholesterol is diagnosed, we will write a referral letter to your ARV clinic or day hospital for further 
management. 
 
It is entirely up to you to decide whether or not to take part in this study. If you do decide to take part, you 
will be asked to sign this consent form. We will then request you to provide us with an extra blood sample 
(15ml) that can be taken at the same time as your normal blood tests and may perform a Chest X Ray. 
 
Although blood testing very rarely causes problems, if anything goes wrong the University provides 
insurance to cover this possibility. This study will also be monitored by the Research Ethics 
Committee of the University of Cape Town. Their job is to ensure your safety and protect you during 
the study. 
 
The decision to participate is entirely your own. IF YOU DECIDE NOT TO PARTICIPATE, YOUR 
TREATMENT WILL NOT BE DIASDVANTAGED IN ANY WAY. In addition, at any point during the 
study you are free to withdraw without telling us why. 
 
Throughout the study your privacy will be maintained and nobody other than the doctors and nurses 
looking after you will know that you are participating. Samples will be labelled with code numbers and 
hence the laboratory staff will not know your identity. When the results of the study become available, 
names of the participating patients will not be included. 
 
Do you have any questions? During the study you may contact either the Human Research Ethics 
Committee (021 406 6492) or Dr Tolullah Oni (021 406 6079) if you have further questions. Please 
remember that Dr Oni will not be directly responsible for your medical care which will be conducted by 
your regular doctors and nurses. 
 
Consent to participate in the study: 
I have read the above / have had the above read to me. I have had the opportunity to discuss the 
study with  _______________________ and have also had the opportunity to ask any questions. I 
consent to  












Date ______________________  
 
Witness (if participant is illiterate) 
 
Name  _____________________ 
 

















































-227.4112						 458.8223	 -	 -	
B	 A	 Age	Category	 -226.1947	 462.3894	 2.43	 0.4875	
C	 A	 Smoker	 -225.7972	 457.5943	 3.23	 0.0724	
D	 A	 Previous	TB	 -223.5753			 453.1507	 7.67	 0.0056	
E	 A	 sex	 -227.3298				 460.6595	 0.16	 0.6866	
F	 A	 Age		 -227.2344			 460.4688	 0.35	 0.5521	




	 	 	 	 	 	
H	 D	 Age	Category	 -222.457	 456.9139	 2.24	 0.5247	
I	 D	 Smoker	 -221.1893	 450.3787	 4.77	 0.0289	
J	 D	 sex	 -223.5726	 455.1452			 0.01	 0.9411	
K	 D	 Age		 -223.5586	 455.1173	 0.03	 0.8550	




	 	 	 	 	 	
M	 L	 Age	Category	 -219.6594	 453.3187			 1.23	 0.7466	
N	 L	 Smoker	 -217.4147	 444.8294	 5.72	 0.0168	
O	 L	 sex	 -220.1067	 450.2135	 0.33	 0.5646	





	 	 	 	 	 	
Q	 N	 Age	Category	 -216.44			 448.88	 1.95	 0.5830	
R	 N	 Sex		 -217.3756				 446.7512	 0.08	 0.7798	





logit  opLL DM hi DMhi prevTB smoker, or 
 
Iteration 0:   log likelihood = -227.71326   
Iteration 1:   log likelihood = -215.58356   
Iteration 2:   log likelihood = -215.54396   
Iteration 3:   log likelihood = -215.54395   
 
Logistic regression                               Number of obs   =        330 
                                                  LR chi2(5)      =      24.34 
                                                  Prob > chi2     =     0.0002 
Log likelihood = -215.54395                       Pseudo R2       =     0.0534 
 
------------------------------------------------------------------------------ 
        opLL | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
          DM |   1.708838    .971891     0.94   0.346     .5605123    5.209745 
          hi |   .6340933    .174845    -1.65   0.099     .3693539    1.088588 
        DMhi |   .2692039   .1882827    -1.88   0.061     .0683512     1.06027 
      prevTB |   2.176119   .5696798     2.97   0.003     1.302714    3.635098 
      smoker |   .5062937   .1430596    -2.41   0.016     .2909947    .8808867 
       _cons |   1.561431   .3812124     1.83   0.068     .9676266    2.519635 
------------------------------------------------------------------------------ 
 
. estat gof 
 
Logistic model for opLL, goodness-of-fit test 
 
       number of observations =       330 
 number of covariate patterns =        14 
              Pearson chi2(8) =         6.72 




























MODEL	 vs	 Variable	included	 log	
likelihood	
AIC	 χ2	 P-value	
A	 -	 Lower	lung	field	cavity	+	Diabetes		 -109.1866	 222.3732	 	 	
B	 A	 Age	Category	 -109.1264	 228.2527	 0.12	 0.9893	
C	 A	 Smoker	 -109.1762				 224.3525					 0.02	 0.8854	
D	 A	 Previous	TB	 -106.589			 -106.589			 5.20	 0.0226	
E	 A	 sex	 -109.1555			 224.3111	 0.06	 0.8031	
F	 A	 Age		 -109.0932	 224.1865	 0.19	 0.6656	





	 	 	 	 	 	
H	 D	 Age	Category	 -106.4944	 224.9888	 0.19	 0.9793	
I	 D	 Smoker	 -106.4848	 220.9697	 0.21	 0.6481	
J	 D	 sex	 -106.5874			 221.1749	 0.00	 0.9557	
K	 D	 Age		 -106.5866				 221.1732	 0.00	 0.9447	





MODEL	 vs	 Variable	included	 log	likelihood	 AIC	 χ2	 P-value	
M	 -	 Diabetes	+	Previous	TB	+	HIV	+	
DM*HIV	
-104.8373						 219.6747	 -	 -	
N	 M	 Age	Category	 -104.6142	 225.2284	 0.45	 0.9305	
O	 M	 Smoker	 -104.6589	 221.3178	 0.36	 0.5503	
P	 M	 sex	 -104.8371	 221.6743	 0.00	 0.9835	





















. logit  cavLLplus DM hi DMhi prevTB, or 
 
Iteration 0:   log likelihood = -109.45792   
Iteration 1:   log likelihood = -105.58037   
Iteration 2:   log likelihood = -104.83906   
Iteration 3:   log likelihood = -104.83734   
Iteration 4:   log likelihood = -104.83734   
 
Logistic regression                               Number of obs   =        330 
                                                  LR chi2(4)      =       9.24 
                                                  Prob > chi2     =     0.0553 
Log likelihood = -104.83734                       Pseudo R2       =     0.0422 
 
------------------------------------------------------------------------------ 
   cavLLplus | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
          DM |   3.919156   2.647622     2.02   0.043     1.042691    14.73091 
          hi |   1.391283   .6799605     0.68   0.499     .5338366    3.625955 
        DMhi |   .1610133   .1658462    -1.77   0.076     .0213851    1.212306 
      prevTB |   2.138036   .8020291     2.03   0.043     1.024965    4.459861 
       _cons |   .0631255   .0280699    -6.21   0.000     .0264061     .150906 
------------------------------------------------------------------------------ 
 
. estat gof 
 
Logistic model for cavLLplus, goodness-of-fit test 
 
       number of observations =       330 
 number of covariate patterns =         8 
              Pearson chi2(3) =         3.96 




























MODEL	 vs	 Variable	included	 log	likelihood	 AIC	 χ2	 P-value	
A	 -	 Isolated	lower	lung	field	involvement	+	Diabetes		 -94.31578			 192.6316	 	 	
B	 A	 Age	Category	 -92.82771	 195.6554	 2.98	 0.3953	
C	 A	 Smoker	 -93.91446			 193.8289	 0.80	 0.3703	
D	 A	 Previous	TB	 -94.19769			 194.3954				 0.24	 0.6270	
E	 A	 sex	 -93.7355			 193.471	 1.16	 0.2813	
F	 A	 Age		 -94.21573	 194.4315	 0.20	 0.6546	














I	 H	 Age	Category	 -91.07533			 196.15
07	
3.88	 0.2743	
J	 H	 Smoker	 -92.65318							 195.30
64	
0.73	 0.3935	
K	 H	 Previous	TB	 -92.79132			 195.58
26	
0.45	 0.5015	
L	 H	 sex	 -92.73194	 195.46
39	
0.57	 0.4501	
























logit onlyLL DM hi DMhi prevTB, or 
 
Iteration 0:   log likelihood =  -95.84989   
Iteration 1:   log likelihood =  -93.06948   
Iteration 2:   log likelihood = -92.791721   
Iteration 3:   log likelihood = -92.791318   
Iteration 4:   log likelihood = -92.791318   
 
Logistic regression                               Number of obs   =        330 
                                                  LR chi2(4)      =       6.12 
                                                  Prob > chi2     =     0.1906 
Log likelihood = -92.791318                       Pseudo R2       =     0.0319 
 
------------------------------------------------------------------------------ 
      onlyLL | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
          DM |   4.899458   4.222524     1.84   0.065     .9048006    26.53037 
          hi |   2.667727   1.716598     1.52   0.127     .7558232    9.415916 
        DMhi |   .3581676    .368689    -1.00   0.319       .04763    2.693347 
      prevTB |   .7367688   .3411842    -0.66   0.509     .2972729    1.826027 
       _cons |   .0397895   .0236191    -5.43   0.000     .0124306    .1273629 
------------------------------------------------------------------------------ 
 
. estat gof 
 
Logistic model for onlyLL, goodness-of-fit test 
 
       number of observations =       330 
 number of covariate patterns =         8 
              Pearson chi2(3) =         2.72 
                  Prob > chi2 =         0.4365 
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D.7	Manuscript	preparation	instructions	(Clinical	Infectious	Disease)	
	
ARTICLE	TYPES	
Papers	may	be	submitted	in	the	following	categories.	The	editors	reserve	the	right	to	change	the	
category	for	consistency	with	CID	style.	
Major	Articles	
Report	clinically	relevant	investigations	or	observations	within	CID	s	scope	of	interests.		
	
Format	guide:		
•	Word	limit:	3000	words	(excluding	the	abstract	and	references).		
•	Key	points	should	be	summarized	on	the	title	page	in	40-words	or	less.		
•	References:	40	or	less.		
•	Abstract:	Up	to	250	words,	structured	using	the	headings	Background,	Methods,	Results	and	
Conclusions.		
•	Tables/Figures:	Data	in	the	text	should	not	be	repeated	extensively	in	tables	or	figures.	
	
MANUSCRIPT	FORMAT	AND	STRUCTURE	
Please	refer	to	a	recent	issue	of	Clinical	Infectious	Diseases	for	guidance	on	style	and	layout	of	
articles.	Also	refer	to	the	Article	type	section	for	guidance	on	relevant	information	for	each	article	
type.	
	
File	Formats	
The	preferred	format	for	submitting	manuscripts	online	is	Microsoft	Word	(.doc	files).	PDF	files	are	
not	acceptable	for	submission.	
	
File	Contents	
Manuscript	.doc	submissions	are	preferred	as	a	single	file,	except	for	figures,	which	can	be	uploaded	
separately.	You	must	also	submit	a	cover	letter	in	a	second	file,	in	the	same	format	as	your	main	file.	
Videos	must	be	submitted	in	the	MPEG	or	Quicktime	format.	For	each	video,	please	submit	a	still	
image	captured	from	the	MPEG	or	Quicktime	file;	this	image	will	appear	as	a	printable	figure	with	
the	article.	A	video	must	have	a	legend	that	will	appear	with	the	still	image.	If	you	wish	to	submit	a	
video,	please	consult	with	the	CID	editorial	office	for	further	details.	
	
Manuscript	Preparation	
Manuscripts	should	be	double-spaced	throughout,	including	the	references	and	the	table	and	figure	
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